Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

4.2%

6 terminated/withdrawn out of 144 trials

Success Rate

83.8%

-2.7% vs industry average

Late-Stage Pipeline

10%

15 trials in Phase 3/4

Results Transparency

3%

1 of 31 completed trials have results

Key Signals

20 recruiting1 with results4 withdrawn

Enrollment Performance

Analytics

Phase 1
31(29.2%)
N/A
31(29.2%)
Phase 2
26(24.5%)
Phase 4
12(11.3%)
Phase 3
3(2.8%)
Early Phase 1
3(2.8%)
106Total
Phase 1(31)
N/A(31)
Phase 2(26)
Phase 4(12)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (144)

Showing 20 of 144 trials
NCT07637877Phase 2Not Yet Recruiting

Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study

Role: lead

NCT07440342Not ApplicableNot Yet Recruiting

TEAS for Sedation During ERCP: A Multicenter Trial With Mechanistic Substudy

Role: lead

NCT05586841Phase 1Completed

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Role: lead

NCT07544121Not ApplicableNot Yet Recruiting

Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis

Role: collaborator

NCT07534371Active Not Recruiting

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

Role: collaborator

NCT07106658Not ApplicableCompleted

TEAS for Variceal Bleeding Endoscopy in Cirrhosis

Role: lead

NCT06357806Not ApplicableActive Not Recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Role: lead

NCT07481032Not ApplicableNot Yet Recruiting

Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

Role: collaborator

NCT07299123Phase 1Enrolling By Invitation

Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA

Role: collaborator

NCT07367542Not ApplicableNot Yet Recruiting

Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery

Role: collaborator

NCT07297173Phase 1Recruiting

Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

Role: lead

NCT07238686Phase 2Recruiting

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

Role: lead

NCT03736707Not ApplicableRecruiting

High-Frequency Oscillation Ventilation Versus Conventional Mechanical Ventilation in Very Preterm Infants With Perinatal Acute Respiratory Distress Syndrome: Multicenters Randomized Controlled, Superiority Trial

Role: collaborator

NCT07186621Phase 3Recruiting

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Role: collaborator

NCT04159142Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Role: collaborator

NCT04138719Phase 2Recruiting

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Role: collaborator

NCT06556862Phase 2Not Yet Recruiting

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Role: lead

NCT05939167Phase 1Recruiting

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Role: collaborator

NCT07078591Phase 2Recruiting

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Role: lead

NCT03591796Not ApplicableCompleted

Invasive Ventilation for Neonates With Acute Respiratory Distress Syndrome(ARDS)

Role: collaborator